Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 265,115 shares, an increase of 411.7% from the August 15th total of 51,809 shares. Approximately 6.3% of the shares of the company are sold short. Based on an average daily volume of 1,250,016 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

Several analysts have issued reports on BJDX shares. Wall Street Zen upgraded Bluejay Diagnostics from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Performance

BJDX traded down $0.08 on Friday, reaching $0.93. The company had a trading volume of 95,945 shares, compared to its average volume of 2,574,783. The stock has a market cap of $4.16 million, a P/E ratio of -0.13 and a beta of 0.91. Bluejay Diagnostics has a fifty-two week low of $0.82 and a fifty-two week high of $16.68. The company’s fifty day moving average is $1.06 and its 200 day moving average is $1.92.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Insider Transactions at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt sold 34,938 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider directly owned 92,055 shares in the company, valued at approximately $128,877. This trade represents a 27.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities & Exchange Commission. 18.47% of the stock is owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.